688 research outputs found
Alzheimer's Disease: A Survey
Alzheimer's Diseases (AD) is one of the type of dementia. This is one of the harmful disease which can lead to death and yet there is no treatment. There is no current technique which is 100% accurate for the treatment of this disease. In recent years, Neuroimaging combined with machine learning techniques have been used for detection of Alzheimer's disease. Based on our survey we came across many methods like Convolution Neural Network (CNN) where in each brain area is been split into small three dimensional patches which acts as input samples for CNN. The other method used was Deep Neural Networks (DNN) where the brain MRI images are segmented to extract the brain chambers and then features are extracted from the segmented area. There are many such methods which can be used for detection of Alzheimer’s Disease
Alzheimers Disease Diagnosis using Machine Learning: A Review
Alzheimers Disease AD is an acute neuro disease that degenerates the brain
cells and thus leads to memory loss progressively. It is a fatal brain disease
that mostly affects the elderly. It steers the decline of cognitive and
biological functions of the brain and shrinks the brain successively, which in
turn is known as Atrophy. For an accurate diagnosis of Alzheimers disease,
cutting edge methods like machine learning are essential. Recently, machine
learning has gained a lot of attention and popularity in the medical industry.
As the illness progresses, those with Alzheimers have a far more difficult time
doing even the most basic tasks, and in the worst case, their brain completely
stops functioning. A persons likelihood of having early-stage Alzheimers
disease may be determined using the ML method. In this analysis, papers on
Alzheimers disease diagnosis based on deep learning techniques and
reinforcement learning between 2008 and 2023 found in google scholar were
studied. Sixty relevant papers obtained after the search was considered for
this study. These papers were analysed based on the biomarkers of AD and the
machine-learning techniques used. The analysis shows that deep learning methods
have an immense ability to extract features and classify AD with good accuracy.
The DRL methods have not been used much in the field of image processing. The
comparison results of deep learning and reinforcement learning illustrate that
the scope of Deep Reinforcement Learning DRL in dementia detection needs to be
explored.Comment: 10 pages and 3 figure
Machine Learning for Multiclass Classification and Prediction of Alzheimer\u27s Disease
Alzheimer\u27s disease (AD) is an irreversible neurodegenerative disorder and a common form of dementia. This research aims to develop machine learning algorithms that diagnose and predict the progression of AD from multimodal heterogonous biomarkers with a focus placed on the early diagnosis. To meet this goal, several machine learning-based methods with their unique characteristics for feature extraction and automated classification, prediction, and visualization have been developed to discern subtle progression trends and predict the trajectory of disease progression.
The methodology envisioned aims to enhance both the multiclass classification accuracy and prediction outcomes by effectively modeling the interplay between the multimodal biomarkers, handle the missing data challenge, and adequately extract all the relevant features that will be fed into the machine learning framework, all in order to understand the subtle changes that happen in the different stages of the disease. This research will also investigate the notion of multitasking to discover how the two processes of multiclass classification and prediction relate to one another in terms of the features they share and whether they could learn from one another for optimizing multiclass classification and prediction accuracy.
This research work also delves into predicting cognitive scores of specific tests over time, using multimodal longitudinal data. The intent is to augment our prospects for analyzing the interplay between the different multimodal features used in the input space to the predicted cognitive scores. Moreover, the power of modality fusion, kernelization, and tensorization have also been investigated to efficiently extract important features hidden in the lower-dimensional feature space without being distracted by those deemed as irrelevant.
With the adage that a picture is worth a thousand words, this dissertation introduces a unique color-coded visualization system with a fully integrated machine learning model for the enhanced diagnosis and prognosis of Alzheimer\u27s disease. The incentive here is to show that through visualization, the challenges imposed by both the variability and interrelatedness of the multimodal features could be overcome. Ultimately, this form of visualization via machine learning informs on the challenges faced with multiclass classification and adds insight into the decision-making process for a diagnosis and prognosis
AI and Non AI Assessments for Dementia
Current progress in the artificial intelligence domain has led to the
development of various types of AI-powered dementia assessments, which can be
employed to identify patients at the early stage of dementia. It can
revolutionize the dementia care settings. It is essential that the medical
community be aware of various AI assessments and choose them considering their
degrees of validity, efficiency, practicality, reliability, and accuracy
concerning the early identification of patients with dementia (PwD). On the
other hand, AI developers should be informed about various non-AI assessments
as well as recently developed AI assessments. Thus, this paper, which can be
readable by both clinicians and AI engineers, fills the gap in the literature
in explaining the existing solutions for the recognition of dementia to
clinicians, as well as the techniques used and the most widespread dementia
datasets to AI engineers. It follows a review of papers on AI and non-AI
assessments for dementia to provide valuable information about various dementia
assessments for both the AI and medical communities. The discussion and
conclusion highlight the most prominent research directions and the maturity of
existing solutions.Comment: 49 page
Recommended from our members
Modelling prognostic trajectories in Alzheimer’s disease
Progression to dementia due to Alzheimer’s Disease (AD) is a long and protracted process that involves multiple pathways of disease pathophysiology. Predicting these dynamic changes has major implications for timely and effective clinical management in AD. There are two reasons why at present we lack appropriate tools to make such predictions. First, a key feature of AD is the interactive nature of the relationships between biomarkers, such as accumulation of β-amyloid -a peptide that builds plaques between nerve cells-, tau -a protein found in the axons of nerve cells- and widespread neurodegeneration. Current models fail to capture these relationships because they are unable to successfully reduce the high dimensionality of biomarkers while exploiting informative multivariate relationships. Second, current models focus on simply predicting in a binary manner whether an individual will develop dementia due to AD or not, without informing clinicians about their predicted disease trajectory. This can result in administering inefficient treatment plans and hindering appropriate stratification for clinical trials. In this thesis, we overcome these challenges by using applied machine learning to build predictive models of patient disease trajectories in the earliest stages of AD. Specifically, to exploit the multi-dimensionality of biomarker data, we used a novel feature generation methodology Partial Least Squares regression with recursive feature elimination (PLSr-RFE). This method applies a hybrid-feature selection and feature construction method that captures co-morbidities in cognition and pathophysiology, resulting in an index of Alzheimer’s disease atrophy from structural MRI. We validated our choice of biomarker and the efficacy of our methodology by showing that the learnt pattern of grey matter atrophy is highly predictive of tau accumulation in an independent sample. Next, to go beyond predicting binary outcomes to deriving individualised prognostic scores of cognitive decline due to AD, we used a novel trajectory modelling approach (Generalised Metric Learning Vector Quantization – Scalar projection) that mines multimodal data from large AD research cohorts. Using this approach, we derive individualised prognostic scores of cognitive decline due to AD, revealing interactive cognitive, and biological factors that improve prediction accuracy. Next, we extended our machine learning framework to classify and stage early AD individuals based on future pathological tau accumulation. Our results show that the characteristic spreading pattern of tau in early AD can be predicted by baseline biomarkers, particularly when stratifying groups using multimodal data. Further, we showed that our prognostic index predicts individualised rates of future tau accumulation with high accuracy and regional specificity in an independent sample of cognitively unimpaired individuals. Overall, our work used machine learning to combine continuous information from AD biomarkers predicting pathophysiological changes at different stages in the AD cascade. The approaches presented in this thesis provide an excellent framework to support personalised clinical interventions and guide effective drug discovery trials
DEEP-AD: The deep learning model for diagnostic classification and prognostic prediction of alzheimer's disease
In terms of context, the aim of this dissertation is to aid neuroradiologists in their clinical judgment regarding the early detection of AD by using DL. To that aim, the system design research methodology is suggested in this dissertation for achieving three goals.
The first goal is to investigate the DL models that have performed well at identifying patterns associated with AD, as well as the accuracy so far attained, limitations, and gaps. A systematic review of the literature (SLR) revealed a shortage of empirical studies on the early identification of AD through DL. In this regard, thirteen empirical studies were identified and examined. We concluded that three-dimensional (3D) DL models have been generated far less often and that their performance is also inadequate to qualify them for clinical trials.
The second goal is to provide the neuroradiologist with the computer-interpretable information they need to analyze neuroimaging biomarkers. Given this context, the next step in this dissertation is to find the optimum DL model to analyze neuroimaging biomarkers. It has been achieved in
two steps. In the first step, eight state-of-the-art DL models have been implemented by training from scratch using end-to-end learning (E2EL) for two binary classification tasks (AD vs. CN and AD vs. stable MCI) and compared by utilizing MRI scans from the publicly accessible datasets of neuroimaging biomarkers. Comparative analysis is carried out by utilizing efficiency-effects graphs, comprehensive indicators, and ranking mechanisms. For the training of the AD vs. sMCI task, the EfficientNet-B0 model gets the highest value for the comprehensive indicator and has the fewest parameters. DenseNet264 performed better than the others in terms of evaluation matrices, but since it has the most parameters, it costs more to train. For the AD vs. CN task by DenseNet264, we achieved 100% accuracy for training and 99.56% accuracy for testing. However, the classification accuracy was still only 82.5% for the AD vs. sMCI task. In the second step, fusion of transfer learning (TL) with E2EL is applied to train the EfficientNet-B0 for the AD vs. sMCI task, which achieved 95.29% accuracy for training and 93.10% accuracy for testing. Additionally, we have also implemented EfficientNet-B0 for the multiclass AD vs. CN vs. sMCI classification task with E2EL to be used in ensemble of models and achieved 85.66% training accuracy and 87.38% testing accuracy.
To evaluate the model’s robustness, neuroradiologists must validate the implemented model. As a result, the third goal of this dissertation is to create a tool that neuroradiologists may use at their convenience. To achieve this objective, this dissertation proposes a web-based application (DEEP-AD) that has been created by making an ensemble of Efficient-Net B0 and DenseNet 264 (based on the contribution of goal 2).
The accuracy of a DEEP-AD prototype has undergone repeated evaluation and improvement. First, we validated 41 subjects of Spanish MRI datasets (acquired from HT Medica, Madrid, Spain), achieving an accuracy of 82.90%, which was later verified by neuroradiologists. The results of these evaluation studies showed the accomplishment of such goals and relevant directions for future research in applied DL for the early detection of AD in clinical settings.En términos de contexto, el objetivo de esta tesis es ayudar a los neurorradiólogos en su juicio clínico sobre la detección precoz de la AD mediante el uso de DL. Para ello, en esta tesis se propone la metodología de investigación de diseño de sistemas para lograr tres objetivos.
El segundo objetivo es proporcionar al neurorradiólogo la información interpretable por ordenador que necesita para analizar los biomarcadores de neuroimagen. Dado este contexto, el siguiente paso en esta tesis es encontrar el modelo DL óptimo para analizar biomarcadores de neuroimagen. Esto se ha logrado en dos pasos. En el primer paso, se han implementado ocho modelos DL de última generación mediante entrenamiento desde cero utilizando aprendizaje de extremo a extremo (E2EL) para dos tareas de clasificación binarias (AD vs. CN y AD vs. MCI estable) y se han comparado utilizando escaneos MRI de los conjuntos de datos de biomarcadores de neuroimagen de acceso público. El análisis comparativo se lleva a cabo utilizando gráficos de efecto-eficacia, indicadores exhaustivos y mecanismos de clasificación. Para el entrenamiento de la tarea AD vs. sMCI, el modelo EfficientNet-B0 obtiene el valor más alto para el indicador exhaustivo y tiene el menor número de parámetros. DenseNet264 obtuvo mejores resultados que los demás en términos de matrices de evaluación, pero al ser el que tiene más parámetros, su entrenamiento es más costoso. Para la tarea AD vs. CN de DenseNet264, conseguimos una accuracy del 100% en el entrenamiento y del 99,56% en las pruebas. Sin embargo, la accuracy de la clasificación fue sólo del 82,5% para la tarea AD vs. sMCI. En el segundo paso, se aplica la fusión del aprendizaje por transferencia (TL) con E2EL para entrenar la EfficientNet-B0 para la tarea AD vs. sMCI, que alcanzó una accuracy del 95,29% en el entrenamiento y del 93,10% en las pruebas. Además, también hemos implementado EfficientNet-B0 para la tarea de clasificación multiclase AD vs. CN vs. sMCI con E2EL para su uso en conjuntos de modelos y hemos obtenido una accuracy de entrenamiento del 85,66% y una precisión de prueba del 87,38%.
Para evaluar la solidez del modelo, los neurorradiólogos deben validar el modelo implementado. Como resultado, el tercer objetivo de esta disertación es crear una herramienta que los neurorradiólogos puedan utilizar a su conveniencia. Para lograr este objetivo, esta disertación propone una aplicación basada en web (DEEP-AD) que ha sido creada haciendo un ensemble de Efficient-Net B0 y DenseNet 264 (basado en la contribución del objetivo 2).
La accuracy del prototipo DEEP-AD ha sido sometida a repetidas evaluaciones y mejoras. En primer lugar, validamos 41 sujetos de conjuntos de datos de MRI españoles (adquiridos de HT Medica, Madrid, España), logrando una accuracy del 82,90%, que posteriormente fue verificada por neurorradiólogos. Los resultados de estos estudios de evaluación mostraron el cumplimiento de dichos objetivos y las direcciones relevantes para futuras investigaciones en DL, aplicada en la detección precoz de la AD en entornos clínicos.Escuela de DoctoradoDoctorado en Tecnologías de la Información y las Telecomunicacione
Unveiling Key Features: A Comparative Study of Machine Learning Models for Alzheimer\u27s Detection
This thesis rigorously evaluates the application of an array of natural language processing (NLP) techniques and machine learning models to identify linguistic signatures indicative of dementia, as sourced from the DementiaBank Pitt corpus. Utilizing a binary classification paradigm, this study meticulously integrates sophisticated embedding methods—including Doc2Vec, Word2Vec, GloVe, and BERT—with traditional machine learning algorithms such as Random Forest, Multinomial Naïve Bayes, ADA boost, KNN classifier, and Logistic Regression, alongside deep learning architectures like LSTM, Bi-LSTM, and CNN-LSTM. The efficacy of these methodologies is evaluated based on their capacity to differentiate between transcribed speech impacted by dementia and that from control subjects. To enhance interpretability, this research also employs feature importance analysis through LIME, SHAP, permutation importance, and integrated gradients, shedding light on the variables most instrumental in driving model predictions. The results of this comprehensive analysis not only illuminate the robust potential of these combined NLP and machine learning approaches in the context of medical screening but also contribute additional valuable insights to the field of NLP and dementia screening specifically
The Characterization of Alzheimer’s Disease and the Development of Early Detection Paradigms: Insights from Nosology, Biomarkers and Machine Learning
Alzheimer’s Disease (AD) is the only condition in the top ten leading causes of death for which we do not have an effective treatment that prevents, slows, or stops its progression. Our ability to design useful interventions relies on (a) increasing our understanding of the pathological process of AD and (b) improving our ability for its early detection. These goals are impeded by our current reliance on the clinical symptoms of AD for its diagnosis. This characterizations of AD often falsely assumes a unified, underlying AD-specific pathology for similar presentations of dementia that leads to inconsistent diagnoses. It also hinges on postmortem verification, and so is not a helpful method for identifying patients and research subjects in the beginning phases of the pathophysiological process. Instead, a new biomarker-based approach provides a more biological understanding of the disease and can detect pathological changes up to 20 years before the clinical symptoms emerge. Subjects are assigned a profile according to their biomarker measures of amyloidosis (A), tauopathy (T) and neurodegeneration (N) that reflects their underlying pathology in vivo. AD is confirmed as the underlying pathology when subjects have abnormal values of both amyloid and tauopathy biomarkers, and so have a biomarker profile of A+T+(N)- or A+T+(N)+. This new biomarker based characterization of AD can be combined with machine learning techniques in multimodal classification studies to shed light on the elements of the AD pathological process and develop early detection paradigms. A guiding research framework is proposed for the development of reliable, biologically-valid and interpretable multimodal classification models
- …